dc.contributor.author | Natukunda, Bernard | |
dc.contributor.author | Ndeezi, Grace | |
dc.contributor.author | Er, Lay See | |
dc.contributor.author | Bajunirwe, Francis | |
dc.contributor.author | Teramura, Gayle | |
dc.contributor.author | Delaney, Meghan | |
dc.date.accessioned | 2021-12-01T07:18:12Z | |
dc.date.available | 2021-12-01T07:18:12Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Natukunda, B., Ndeezi, G., See Er, L., Bajunirwe, F., Teramura, G., & Delaney, M. (2019). The role of improved pre‐transfusion testing in the prevention of delayed serologic transfusion reactions among blood recipients in Uganda: a Randomized Controlled Trial (IPAT Study). ISBT Science Series, 14(4), 366-373. | en_US |
dc.identifier.issn | 366-373 | |
dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/1049 | |
dc.description.abstract | Background and objectives: The goal of pre-transfusion testing (PTT) is to provide patients with beneficial and safe transfusions. In Uganda, PTT includes ABO/RhD typing plus room temperature (RT) saline cross-matches without red-blood-cell (RBC) alloantibody screening. The aim of the IPAT study was to assess the role of improved PTT in the prevention of delayed serologic transfusion reactions (DSTRs).
Materials and methods: In this randomized controlled trial, patients at Mbarara Hospital in Uganda, with a history of RBC exposure, were randomized 1:1 to have either RBC alloantibody screening (SCREEN group) or room temperature saline cross-matches (CONTROL group) during PTT. ‘Home-made’ reagent RBCs from group O RhD-positive volunteers were used for antibody screening in the indirect antiglobulin test. Participants were evaluated for RBC alloantibody production 7– 14 days after transfusion. Post-transfusion haemoglobin estimation and direct
antiglobulin tests (DATs) were also performed.
Results: We randomized 220 patients to either the SCREEN or CONTROL group. Both study arms had similar demographic and transfusion characteristics at baseline. There were 19 (17_3%) individuals in the CONTROL group with DSTRs compared to 8 (7_3%) in the SCREEN group at the time of follow-up (P = 0_02). Overall, post-transfusion DATs were positive in 7 (3_5%) patients but there was no associated decrease in haemoglobin levels.
Conclusion: Red-blood-cell alloantibody screening is associated with occurrence of significantly fewer DSTRs. The use of ‘home-made’ reagent cells during PTT in Uganda is feasible. We recommend a change in the local PTT policy to consider the introduction of RBC alloantibody screening. | en_US |
dc.description.sponsorship | Swedish International Development Cooperation Agency (Sida) | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ISBT Science Series | en_US |
dc.subject | Blood transfusion | en_US |
dc.subject | Delayed serologic transfusion reactions | en_US |
dc.subject | Pre-transfusion testing | en_US |
dc.subject | RBC alloantibody screening | en_US |
dc.subject | Uganda | en_US |
dc.title | The role of improved pre-transfusion testing in the prevention of delayed serologic transfusion reactions among blood recipients in Uganda: a Randomized Controlled Trial (IPAT Study) | en_US |
dc.type | Article | en_US |